Table 2.
Metabolic parameter values according to clinical characteristics and statistical associations between clinical and metabolic parameters
| Clinical parameter | Mean MTV (95% CI) | P value | Mean TLG (95% CI) | P value | Mean SUVmax (95% CI) | P value | Mean SUVpeak (95% CI) | P value |
| Age category | ||||||||
| <75 years | 69.0 (43.4–94.6) | 511 (259–764) | 15.0 (12.6–17.4) | 11.2 (9.3–13.1) | ||||
| ≥75 years | 69.0 (33.8–104) | 0.23 | 437 (231–643) | 0.43 | 15.0 (11.8–18.3) | 0.47 | 10.2 (8.5–12.0) | 0.68 |
| Gender | ||||||||
| Male | 77.3 (49.8–105) | 584 (309–859) | 14.5 (12.6–16.3) | 10.5 (8.9–12.0) | ||||
| Female | 47.7 (19.5–75.9) | 0.18 | 269 (146–391) | 0.21 | 16.4 (10.8–22.0) | 0.86 | 12.3 (7.91–16.8) | 0.98 |
| Histological type | ||||||||
| NSC | 71.2 (46.7–96.6) | 498 (264–733) | 14.6 (12.3–16.8) | 10.9 (9.1–12.6) | ||||
| SC | 55.0 (27.4–82.5) | 0.67 | 479 (160–798) | 0.48 | 17.3 (13.1–21.4) | 0.12 | 11.8 (9.2–14.4) | 0.23 |
| Prior chemotherapy | ||||||||
| Yes | 55.3 (37.7–73.0) | 437 (213–662) | 15.6 (13.3–18.0) | 11.4 (9.62–13.2) | ||||
| No | 134 (49.9–218) | 0.04 | 773 (312–1233) | 0.17 | 12.0 (9.1–14.9) | 0.18 | 9.1 (6.84–11.3) | 0.28 |
| Prior local treatment | ||||||||
| Yes | 45.4 (27.6–63.2) | 242.6 (162–323) | 14.4 (10.6–18.2) | 10.3 (7.42–13.1) | ||||
| No | 86.6 (52.4–121) | 0.04 | 684 (344–1023) | 0.02 | 15.4 (13.3–17.6) | 0.15 | 11.6 (9.89–13.2) | 0.45 |
| PDL1 expression | ||||||||
| <50% | 66.9 (17.5–116) | 479 (132–827) | 18.2 (10.8–25.6) | 13.3 (7.33–19.2) | ||||
| ≥50% | 91.9 (48.2–136) | 0.14 | 706 (259–1153) | 0.35 | 14.4 (11.9–16.9) | 0.56 | 10.7 (8.84–12.7) | 0.87 |
Bold values have statistically significant differences.
MTV, whole-body metabolic tumor volume; NSC, non-squamous cell carcinoma; PDL1, programmed death receptor ligand 1; SC, squamous cell carcinoma; SUVmax, maximum standardized uptake value; SUVpeak, peak standardized uptake value; TLG, whole-body total lesion glycolysis.